Drug and Alcohol Dependence
Volume 107, Issue 2 , Pages 188-195 , 1 March 2010

A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers

  • Andrea H. Weinberger

      Affiliations

    • Program for Research in Smokers with Mental Illness (PRISM), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Corresponding Author InformationCorresponding author at: Department of Psychiatry, Yale University School of Medicine, 34 Park Street, SAC, Room S-211, New Haven, CT 06519, USA. Tel.: +1 203 974 7598; fax: +1 203 974 7366.
    • ,
  • Erin L. Reutenauer

      Affiliations

    • Program for Research in Smokers with Mental Illness (PRISM), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • ,
  • Peter I. Jatlow

      Affiliations

    • Departments of Laboratory Medicine and Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • ,
  • Stephanie S. O’Malley

      Affiliations

    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • ,
  • Marc N. Potenza

      Affiliations

    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Child Study Center, Yale University School of Medicine, New Haven, CT 06519, USA
    • ,
  • Tony P. George

      Affiliations

    • Program for Research in Smokers with Mental Illness (PRISM), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Division of Addiction Psychiatry, Department of Psychiatry, University of Toronto and Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, M5T 1R8 Canada

Received 31 July 2009 ,Revised 16 October 2009 ,Accepted 19 October 2009.

References 

  1. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin. Psychol. Rev. 1988;8:77–100
  2. Benowitz NL, Jacob P, Ahijevich K, Jarvis MJ, Hall S, LeHouzec J, et al. Biochemical verification of tobacco use and cessation. Report from the SRNT Subcommittee on Biochemical Verification. Nicotine Tob. Res. 2002;4:149–159
  3. Berlin, I., Aubin, H.-J., Pedarriosse, A.M., Rames, A., Lazabemide in Smoking Cessation Study Investigators, Lancrenon, S., Lagrue, G., 2002. Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Addiction 97, 1347–1354.
  4. Berlin I, Said S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin. Pharmacol. Ther. 1995;58:444–452
  5. Biberman R, Neumann R, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction. 2003;98:1403–1407
  6. Biener L, Abrams DB. The Contemplation Ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol. 1991;10:360–365
  7. Bland JM, Altman DG. Survival probabilities (the Kaplan–Meier Method). BMJ. 1998;317:1572
  8. Cahill L. Why sex matters for neuroscience. Nat. Rev. Neurosci. 2006;7:477–491
  9. CDC, 2009. Annual smoking-attributable mortality, years of potential life lost, and economic costs—United States, 1998–2007. Morbidity and Mortality World Report (MMWR) 58, 221–226.
  10. Dickerson DL, Leeman RF, Mazure CM, O’Malley SS. The inclusion of women and minorities in smoking cessation clinical trials: a systematic review. Am. J. Addict. 2009;18:21–28
  11. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: U.S. Department of Health and Human Services; 2008;
  12. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, DC: American Psychiatric Press; 1997;
  13. Fowler JS, Logan J, Wang G-J, Volkow ND. Monoamine oxidase and cigarette smoking. NeuroToxicology. 2003;24:75–82
  14. In:  George TP editors. Medication Treatments for Nicotine Dependence. Boca Raton, Florida: Taylor & Francis; 2006;
  15. George TP, O’Malley SS. Current pharmacological treatments for nicotine dependence. Trends Pharmacol. Sci. 2004;25:42–48
  16. George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O’Malley SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol. Psychiatry. 2003;53:136–143
  17. George TP, Weinberger AH. Monoamine oxidase inhibition: potential for developing tobacco pharmacotherapies. Clin. Pharmacol. Therapeut. 2008;83:619–621
  18. Glassman AH, Covey LS, Dalack GW, Stetner F, Rivelli SK, Fleiss J, et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin. Pharmacol. Ther. 1993;54:670–679
  19. Grasing K, He S. Effects of high-dose selegiline on morphine reinforcement and precipitated withdrawal in dependent rats. Behav. Pharmacol. 2005;16:1–13
  20. Guillem K, Vouillac C, Azar MR, Parsons LH, Koob GF, Cador M, et al. Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J. Neurosci. 2005;25:8593–8600
  21. Guillem K, Vouillac C, Azar MR, Parsons LH, Koob GF, Cador M, et al. Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats. Eur. J. Neurosci. 2006;24:3532–3540
  22. Guillem K, Vouillac C, Koob GF, Cador M, Stinus L. Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal-induced place aversion. Biol. Psychiatry. 2008;63:158–163
  23. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960;23:56–62
  24. Hariharan M, VanNoord T, Greden JF. A high-performance liquid chromatographic method for routine simultaneous determination of nicotine and cotinine in plasma. Clin. Chem. 1988;34:724–729
  25. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 1991;86:1119–1127
  26. Houtsmuller EJ, Thornton JA, Stitzer ML. Effects of selegiline (L-deprenyl) during smoking and short-term abstinence. Psychopharmacology. 2002;163:213–220
  27. Hughes JR. The future of smoking cessation therapy in the United States. Addiction. 1996;91:1797–1802
  28. Hughes JR, Hatsukami DK. Signs and symptoms of tobacco withdrawal. Arch. Gen. Psychiatry. 1986;43:289–294
  29. Hughes JR, Keely JP, Niaura RS, Ossip-Klein D, Richmond RL, Swan GE. Measurement of abstinence in clinical trials: issues and recommendations. Nicotine Tob. Res. 2003;5:13–25
  30. Irvin JE, Brandon TH. The increasing recalcitrance of smokers in clinical trials. Nicotine Tob. Res. 2000;2:79–84
  31. Irvin JE, Hendricks PS, Brandon TH. The increasing recalcitrance of smokers in clinical trials II: pharmacotherapy trials. Nicotine Tob. Res. 2003;5:27–35
  32. Levine J, Schooler NR. General versus specific inquiry with SAFTEE. J. Clin. Psychopharmacol. 1992;12:3–10
  33. Lewis A, Miller JH, Lea RA. Monoamine oxidase and tobacco dependence. NeuroToxicology. 2007;28:182–195
  34. MayoClinic . Smoke Free and Living It. Rochester, MN: Mayo Clinic; 2000;
  35. Perkins KA. Smoking cessation in women: special considerations. CNS Drugs. 2001;15:391–411
  36. Perkins KA, Lerman C, Stitzer M, Fonte CA, Briski JL, Scott JA, et al. Development of procedures for early screening of smoking cessation medications in humans. Clin. Pharmacol. Ther. 2008;84:216–221
  37. Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob. Res. 2008;10:1245–1251
  38. Scharf D, Shiffman S. Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of bupropion SR. Addiction. 2004;99:1269–1462
  39. Schiffer WK, Azmoodeh M, Gerasimov M, Volkow ND, Fowler JS, Dewey SL. Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine. Synapse. 2003;48:35–38
  40. Schnoll RA, Wileyto EP, Pinto A, Leone F, Gariti P, Siegel S, et al. A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend. 2008;98:86–93
  41. Siu ECK, Tyndale RF. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J. Pharmacol. Exp. Ther. 2008;324:992–999
  42. Sobell LC, Sobell MB, Leo GI, Cancilla A. Reliability of a timeline method: assessing normal drinkers’ reports of recent drinking and a comparative evaluation across several populations. Br. J. Addict. 1988;83:393–402
  43. Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann. Intern. Med. 2009;150:447–454
  44. Tiffany ST, Drobes DJ. The development and initial validation of a questionnaire on smoking urges. Addiction. 1991;86:1467–1476
  45. Villegier A-S, Lotfipour S, McQuown SC, Belluzzi JD, Leslie FM. Tranylcypromine enhancement of nicotine self-administration. Neuropharmacology. 2007;52:1415–1425
  46. Wooters TE, Bardo MT. The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats. Behav. Pharmacol. 2007;18:601–608

☆ The Clinicaltrials.gov Registration No. for this trial, “Usefulness of Selegiline as an Aid to Quit Smoking,” is NCT00129311.

PII: S0376-8716(09)00399-8

doi: 10.1016/j.drugalcdep.2009.10.009

Drug and Alcohol Dependence
Volume 107, Issue 2 , Pages 188-195 , 1 March 2010

Article Tools

* Image Usage & Resolution